/
QNCX
$18.41-$0.46 (-2.43%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$18.5M
20M shares
52-week range
$15.80 – $909.98
0% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-383.59
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $51.0K | $0 | $0 | $0 | $0 | $0 | $0 | $142.0K |
| Gross profit | −$51.0K | $0 | $0 | $0 | $0 | $0 | $0 | −$142.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $10.1M | $30.2M | $61.3M | $60.8M | $25.2M | $9.4M | $18.6M | $35.4M |
| Operating income | −$12.1M | −$39.2M | −$78.9M | −$90.3M | −$52.0M | −$34.6M | −$57.3M | −$50.4M |
| EBITDA | −$12.1M | −$39.0M | −$78.6M | −$89.6M | −$51.0M | −$26.8M | −$36.0M | −$80.6M |
| Net income | −$12.5M | −$37.0M | −$76.8M | −$89.9M | −$51.7M | −$31.4M | −$56.8M | −$84.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -5.80 | -19.30 | -26.30 | -30.30 | -15.40 | -8.40 | -13.10 | -16.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.24 | $-0.24–$-0.24 | 2 |
| 2027 | $17M | $-1.25 | $-1.25–$-1.25 | 1 |
| 2028 | $292M | $-0.56 | $-4.11–$2.99 | 2 |
| 2029 | $486M | $-1.12 | $-1.12–$-1.12 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Quince Therapeutics, Inc. Common Stock
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
www.quincetx.com- Employees
- 38
- IPO / List date
- May 9, 2019
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds QNCX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in QNCX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-30 | 1-for-20reverse |
| 2026-04-13 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded QNCX yet.
